The Rat FGF-23 (Fibroblast Growth Factor 23) ELISA Kit is specially designed for the precise measurement of FGF-23 levels in rat serum, plasma, and cell culture supernatants. This ELISA kit offers exceptional sensitivity and specificity, ensuring accurate and reproducible results for various research purposes. FGF-23 is a key regulator of phosphate metabolism and plays a critical role in maintaining mineral homeostasis.
Dysregulation of FGF-23 has been linked to renal disorders, cardiovascular diseases, and skeletal abnormalities, making it a valuable biomarker for studying these conditions and exploring potential therapeutic interventions. With its reliable performance and ease of use, the Rat FGF-23 ELISA Kit is an indispensable tool for researchers looking to investigate the role of FGF-23 in health and disease in rat models.
Product Name:
Rat FGF 23/Fibroblast Growth Factor 23 ELISA Kit
SKU:
RTFI00086
Reactivity:
Rat
Assay Type:
Sandwich ELISA, Double Antibody
Sensitivity:
9.375 pg/mL
Range:
15.625-1000 pg/mL
Sample Type:
Serum, Plasma, Cell Culture Supernatant, Cell or Tissue Lysate, Other Liquid Samples
Storage:
2-8°C for 12 months.
Linearity:
Sample
1:2
1:4
1:8
Serum (n = 5)
85-102%
88-99%
85-99%
EDTA Plasma (n = 5)
90-102%
82-101%
80-96%
Heparin Plasma (n = 5)
87-105%
92-100%
82-88%
Recovery:
Sample
Recovery Range (%)
Average (%)
Serum (n = 5)
95-105
99
EDTA Plasma (n = 5)
85-103
92
Heparin Plasma (n = 5)
87-104
96
Note:The below protocol is a sample protocol. Protocols are specific to each batch/lot. For the correct instructions please follow the protocol included in your kit.
Step
Procedure
1
Reagent & Plate Preparation: Equilibrate reagents and TMB substrate to room temperature. Set standard, test sample and control (zero) wells on the pre-coated plate and record their positions.
2
Primary Incubation: Prepare standards, samples, blanks and load into designated wells. Incubate plate at 37°C for 90 minutes to allow antigen binding.
3
Detection Antibody Binding: Add biotin-labeled detection antibody and incubate at 37°C for 60 minutes.
4
HRP-Streptavidin Binding: Add HRP-Streptavidin (SABC) and incubate at 37°C for 30 minutes.
5
Color Development: Add TMB substrate and incubate in the dark for 10–20 minutes.
6
Stop Reaction & Reading: Add stop solution and measure absorbance at 450 nm immediately.
Sample Type
Protocol
Serum
Allow blood to clot, centrifuge at 1000 × g for 20 minutes, collect supernatant supernatant and store appropriately.
Plasma
Collect using anticoagulant tubes, centrifuge at 1000 × g for 15 minutes at 2–8°C and collect plasma.
Tissue Homogenate
Homogenize tissue in PBS with protease inhibitors, centrifuge and collect supernatant.
Cell Culture Supernatant
Centrifuge at 2500 rpm for 5 minutes and collect clarified supernatant.
Cell Lysate
Lyse cells using lysis buffer with protease inhibitors, centrifuge and collect protein supernatant.
Other Sample Types
For more information about how to process other sample types, (e.g., body fluids, breast milk & more), please contact our Tech Support Team at techsupport@assaygenie.com.
Component
Quantity
Storage
48T
96T
ELISA Microplate (Dismountable)
8×6
8×12
Place the test strips into a sealed foil bag with the desiccant. Store for 1 month at 2-8°C; Store for 12 months at -20°C.
Lyophilized Standard
1 vial
2 vial
Place the standards into a sealed foil bag with the desiccant. Store for 1 month at 2-8°C; Store for 12 months at -20°C.
Biotin-labeled Antibody (Concentrated, 100X)
60 ul
120 ul
2-8°C (Avoid direct light)
HRP-Streptavidin Conjugate (SABC, 100X)
60 ul
120 ul
2-8°C (Avoid direct light)
TMB Substrate
5 ml
10 ml
2-8°C (Avoid direct light)
Sample Dilution Buffer
10 ml
20 ml
2-8°C
Antibody Dilution Buffer
5 ml
10 ml
2-8°C
SABC Dilution Buffer
5 ml
10 ml
2-8°C
Stop Solution
5 ml
10 ml
2-8°C
Wash Buffer(25X)
15 ml
30 ml
2-8°C
Plate Sealer
3 pieces
5 pieces
-
Technical Manual
1 copy
1 copy
-
Shymanskyi, I., et al.
Tissue-specific adaptive responses of the vitamin D3 auto-/paracrine system to vitamin D3 deficiency in bone and brain
European Review for Medical and Pharmacological Sciences 2026
